Dr. Reddy's beats profit and revenue estimates in second quarter
Dr. Reddy's Q2 consolidated net profit hit 9.25 billion rupees against a 7.5 billion IBES estimate, with revenue at 86.98 billion, Reuters reports.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Dr. Reddy's Laboratories reported consolidated net profit of 9.25 billion rupees for the second quarter, above the IBES consensus of 7.5 billion rupees.
Revenue from operations came in at 86.98 billion rupees, compared with the 84.84 billion rupees analysts had expected. The figures were published by Reuters.
why it matters
For investors, the beat suggests the Indian drugmaker's core business is performing better than forecast. The result may lift sentiment toward Indian generic pharma stocks, though a single quarterly report rarely shifts the broader market trend.
market impact
Dr. Reddy's shares and Indian pharma sector: earnings above consensus supports the company's stock
tags
instruments
sources
- Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees — Reuters, 23 October 2026 at 12:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗